Plant Name: Mesembryanthemum tortuosum
Taxonomic Information:
Plant ID: NPO12693
Plant Latin Name: Mesembryanthemum tortuosum
Taxonomy Genus: Mesembryanthemum
Taxonomy Family: Aizoaceae
Plant External Links:
NCBI TaxonomyDB:
216016
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Madagascar; Angola; South Africa; Zimbabwe; China; SwazilandTraditional Medicine System:
TCMGeographical Distribution:
Madagascar; Angola; South Africa; Zimbabwe; China; Swaziland
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GAA; | |
| BLM; HPGD; HSD17B10; ALDH1A1; | |
| CA2; CA1; CA12; CA9; CA3; CA14; CA7; CA4; CA6; | |
| HIF1A; TP53; NFKB1; | |
| LMNA; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.893E-08 | 3.748E-05 | BLM, CA1, CA12, CA2, CA3, CA4, CA6, CA7, CA9, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.681E-07 | 6.679E-04 | CYP1A2, CYP2A6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.435E-06 | 5.681E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 4.300E-06 | 5.681E-03 | CYP1A2, CYP2A6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.864E-06 | 9.650E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.329E-24 | 1.378E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.785E-19 | 9.564E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.542E-17 | 2.473E-13 | CA1, CA12, CA2, CA3, CA4, CA6, CA7, CA9 |
| CC | GO:0043226; organelle | GO:0016604; nuclear body | 1.828E-05 | 1.809E-02 | BLM, HIF1A, LMNA, MAPT, SMN1, SMN2, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.213E-05 | 1.927E-02 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.213E-05 | 1.927E-02 | CA1, CA2 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.607E-05 | 4.601E-02 | CA2, CA4, CA9, HPGD |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.245E-23 | 2.200E-21 | CA12, CA1, CA3, CA2, CA4, CA7, CA6, CA9, CA14 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.028E-06 | 5.037E-05 | CYP2A6, CYP1A2, ALDH1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 7.552E-05 | 1.752E-03 | CYP2A6, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.936E-05 | 1.752E-03 | CYP2A6, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.263E-04 | 2.064E-03 | CYP2A6, CYP1A2, CYP3A4 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 6.101E-04 | 6.643E-03 | LMNA, TP53, NFKB1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.377E-05 | 4.498E-04 | CYP2A6, CYP1A2 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.263E-03 | 1.232E-02 | HPGD, TP53, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.493E-04 | 6.643E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 3.438E-04 | 4.814E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
